Draft guideline: Magnesium sulphate prior to preterm birth for Neuroprotection of the fetus, infant and child.

The Guideline is designed to provide practical evidence-based guidance on the best practice for clinical care in the use of magnesium sulphate prior to preterm birth.  The Guideline will be relevant for health professionals who care for women at risk of preterm birth and their babies; for pregnant women and their partners and families; and for policy makers in maternity care.

Invitation to make a submission

The Australia Research Centre for Health of Women and Babies (ARCH) is conducting a public consultation on the draft guideline Comments on the draft guideline are invited.

How to make a submission

Electronic submissions are strongly preferred and should be emailed to arch@adelaide.edu.au. If this is not possible, please make your submission in writing (preferably typed or word processed) and mail to:

Tanya Bubner
Manager, ARCH
Women’s and Children’s Hospital
Queen Victoria Building, level 1
72 King William Street
NORTH ADELAIDE  SA  5006

Please ensure that the author of the submission and organisation (if applicable) is clearly stated.  If you would like your submission to be treated as confidential, please indicate this clearly (for example, by marking CONFIDENTIAL on each page of your written submission).  All submissions will have personal contact details removed prior to becoming publicly available.

How to make a submission

For information on how to make a submission please click here:

Closing Date

The closing date for submissions is close of business Monday 18 January 2010.

Download entire document as pdf

Draft guideline: Magnesium sulphate prior to preterm birth for Neuroprotection of the fetus, infant and child